Global Trends Fuel Expansion in Cell Harvesting System Market
The global cell harvesting system market is on the cusp of significant expansion, underpinned by accelerating demand in regenerative medicine, personalized therapies, and biopharmaceutical manufacturing. According to the latest projections, the market is poised to reach a valuation of US$ 15.5 billion by 2032, expanding from US$ 6.9 billion in 2025, and charting a compound annual growth rate (CAGR) of 12.2% between 2025 and 2032.
This surge reflects an industry undergoing rapid technological evolution, shifting away from traditional manual processes to automated systems that deliver higher efficiency, precision, and scalability—attributes increasingly crucial for large-scale cell-based applications and personalized medicine.
Transforming Biomanufacturing: From Manual Processes to Automation
Cell harvesting, the process of isolating target cells from growth media, has traditionally relied on manual techniques such as centrifugation and depth filtration. However, as the complexity of biologic drugs, cell therapies, and regenerative medicines escalates, these manual systems are proving inadequate for the stringent demands of modern biomanufacturing.
Industry players have responded with a wave of innovation. Automated solutions such as single-use centrifuges, robotic liquid handlers, and closed-system technologies are revolutionizing cell harvesting. Notably, Thermo Fisher Scientific in October 2022 introduced the DynaSpin Single-Use Centrifuge, which reduces filter usage six-fold and decreases waste by 70% compared to conventional systems—a compelling proposition for manufacturers seeking sustainability alongside operational efficiency.
Similarly, in May 2024, Cytiva, in collaboration with Kite (a Gilead company), unveiled the Sefia cell therapy manufacturing platform. This modular system automates critical CAR-T therapy processes, from cell isolation to expansion, through closed, digitally integrated workflows, minimizing contamination risk and aligning with stringent regulatory expectations such as those set forth by the FDA’s Emerging Technology Program.
Automation: The Engine of Market Growth
Automated cell harvesting systems are expected to account for a commanding 67.4% market share by 2025, underscoring the industry’s decisive pivot away from manual processes. The benefits are manifold: reduced human error, improved reproducibility, higher throughput, and scalability—all crucial for biopharmaceutical applications that demand consistency and speed.
“Automation is no longer optional—it’s become essential for companies striving to remain competitive in the era of advanced biologics and cell therapies,” remarked an industry analyst at Global Business Insights. “The investment in automation upfront is significant, but the long-term benefits in operational savings, process consistency, and regulatory compliance are proving transformative.”
Indeed, automated platforms now integrate sophisticated analytics, enabling real-time monitoring and quality control. Advances in tangential flow filtration (TFF) and continuous centrifugation are further pushing boundaries, enabling faster turnaround times and cost-effective production.
Biopharmaceuticals Dominate Application Segments
Biopharmaceutical applications are projected to maintain a dominant foothold in the cell harvesting system market through 2025 and beyond. The biopharma industry is heavily reliant on cell harvesting technologies for the production of monoclonal antibodies, vaccines, and increasingly, cell-based therapies such as CAR-T and stem cell treatments.
This dynamic reflects surging investment in biopharmaceutical R&D, driven by both established pharmaceutical giants and a proliferating ecosystem of biotech startups. The market’s growth is reinforced by a rising demand for personalized medicines targeting chronic and complex diseases, which require precision harvesting and processing of patient-specific cells.
Cost and Complexity Remain Key Barriers
Despite robust growth, the market faces headwinds. High capital expenditure associated with automated systems and complex qualification protocols remains a significant barrier to widespread adoption, particularly among smaller biotech firms and legacy manufacturing facilities entrenched in traditional methods.
Transitioning to automated systems often entails rigorous validation and multiple test runs to define operational parameters, prolonging timelines and elevating costs. While regulatory bodies such as the FDA and EMA have signalled strong support for technological innovation, uneven uptake across facilities limits economies of scale and slows overall market penetration.
Emerging Opportunities: From Novel Microcarriers to AI Integration
Yet, the sector’s momentum remains strong, with emerging technologies promising new avenues for growth. In November 2024, Rousselot and IamFluidics announced a dissolvable microcarrier developed using patented IN-AIR MICROFLUIDICS™ technology. This breakthrough simplifies adherent cell harvesting and enables scalable production of cell therapies and biologics.
Similarly, systems like AVISO’s CellCelector, equipped with robotic arms for precise cell selection, exemplify how automation is pushing the envelope in single-cell handling—an area critical for developing next-generation personalized therapies.
The integration of artificial intelligence (AI) and machine learning (ML) is further reshaping the market landscape. AI-driven analytics are optimizing process parameters in real time, enhancing yields, and improving scalability. Innovative lab-on-a-chip (LOC) devices and 3D-printed microfluidic systems are enabling continuous stem cell harvesting on an industrial scale without compromising cell viability.
“Technologies such as AI and microfluidics are shifting cell harvesting from a manual, error-prone process into a digitally driven, highly controlled operation,” said a senior executive at a leading biotech instrumentation firm. “These solutions are the key to unlocking the next frontier of regenerative medicine and biomanufacturing.”
Regional Dynamics: North America Leads, Asia Pacific Emerges
Regionally, North America is projected to dominate the global cell harvesting system market, commanding a 38.6% value share in 2025. The region benefits from advanced biopharmaceutical infrastructure, a robust pipeline of cell-based research, and substantial government and private investments. Between 1996 and 2020, over 200 new drugs and vaccines were developed through university-industry collaborations in the U.S., fueling demand for high-performance cell harvesting systems.
Moreover, U.S. biopharmaceutical firms continue to outpace global peers in R&D investment, with 193 of the top 260 R&D-intensive firms headquartered in the United States as of 2021, each spending an average of $637,735 per employee annually.
Europe is emerging as a significant growth hub, propelled by strong regulatory support and strategic investments. Initiatives like Germany’s new Collaborative Research Centres and Novartis’ GMP-ready manufacturing facility in Austria, slated to produce 1.7 million litres of cell culture harvest annually, underscore Europe’s commitment to advanced biomanufacturing.
Meanwhile, Asia Pacific is rapidly gaining prominence. Governments across the region are funneling significant resources into regenerative medicine and cell therapy research. In December 2023, FUJIFILM Corporation announced a US$200 million investment to enhance cell therapy CDMO capabilities, highlighting the region’s strategic importance. Rising chronic disease prevalence and expanding biotech hubs further drive demand, positioning Asia Pacific as a key growth engine in the coming decade.
Competitive Landscape: Innovation and Strategic Partnerships
The competitive landscape of the cell harvesting system market is marked by intense innovation and strategic collaborations. Leading firms such as Esco Micro Pte. Ltd., Sartorius AG, Cytiva (Danaher), Thermo Fisher Scientific Inc., Beckman Coulter, and Corning Incorporated continue to expand product portfolios through technological breakthroughs and mergers and acquisitions.
Recent developments include Sphere Fluidics’ launch in June 2025 of CytoMine Chroma, a platform that enhances single-cell analysis through multiplex fluorescence detection, streamlining biopharma workflows for precision cell harvesting. In December 2024, Ori Biotech Ltd. joined forces with Fresenius Kabi to integrate Ori’s IRO® platform with the Cue® and Lovo® Cell Processing Systems, aiming to create a seamless, closed-system cell therapy manufacturing solution.
These strategic moves underscore a market characterized by rapid technological change and a relentless focus on efficiency, scalability, and regulatory compliance.
Read Related Reports:
.png)
Comments
Post a Comment